Drug Trial Radar · NCT01951638
Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)
Last checked: Nov 20, 2026Latest source record: Mar 16, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
477
Actual
Start
Nov 6, 2013
Primary completion
Aug 18, 2015
Study completion Sep 16, 2015
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Sep 26, 2013
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Objective of the study is to find the optimal dose of the once daily oral soluble guanylate cyclase stimulator (sGC) BAY1021189 for Phase III that can be given in addition to standard diuretic and comorbidity treatment for heart failure with preserved ejection fraction (HFpEF)
Conditions
- Heart Failure
Interventions
Vericiguat (BAY1021189) (1.25 mg)Drug
1.25 mg BAY1021189 tablets
Vericiguat (BAY1021189) (5 mg)Drug
5 mg BAY1021189 tablets
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to Week 12 in Log-transformed N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)Time frame: Baseline, Week 12 (end of treatment [EOT])
- Change From Baseline to Week 12 in Left Atrial Volume (LAV)Time frame: Baseline, Week 12 (EOT)
Locations
158 sites in 25 countries. Site status is shown where the registry gives one.
Site not named
Fountain Valley, California
Site not named
Fort Lauderdale, Florida
Site not named
Naples, Florida
Site not named
Macon, Georgia
Site not named
Chicago, Illinois
Site not named
Iowa City, Iowa
Site not named
New Orleans, Louisiana
Site not named
Detroit, Michigan
Site not named
Minneapolis, Minnesota
Site not named
Jackson, Mississippi
Site not named
Newark, New Jersey
Site not named
Buffalo, New York
Site not named
Pittsburgh, Pennsylvania
Site not named
Charleston, South Carolina
Site not named
Germantown, Tennessee
Site not named
Nashville, Tennessee
Site not named
Milwaukee, Wisconsin
Site not named
Darlinghurst, New South Wales, Australia
Site not named
Brisbane, Queensland, Australia
Site not named
Brisbane, Queensland, Australia
Site not named
Redcliffe, Queensland, Australia
Site not named
Hobart, Tasmania, Australia
Site not named
Salzburg, Austria
Site not named
Vienna, Austria
Site not named
Vienna, Austria
Site not named
Sankt Pölten, Lower Austria, Austria
Site not named
Graz, Styria, Austria
Site not named
Linz, Upper Austria, Austria
Site not named
Linz, Upper Austria, Austria
Site not named
Bruges, Belgium
Site not named
Bruxelles - Brussel, Belgium
Site not named
Ghent, Belgium
Site not named
Gilly, Belgium
Site not named
Huy, Belgium
Site not named
Mechelen, Belgium
Site not named
Mol, Belgium
Site not named
Roeselare, Belgium
Site not named
Burgas, Bulgaria
Site not named
Sofia, Bulgaria
Site not named
Sofia, Bulgaria
Showing 40 of 158 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.